Sol-Gel Technologies

Headquarters: Ness Ziona, Israel

Investor Relations: Irina Koffler / +1 917 734 7387 / ikoffler@lifesciadvisors.com

Description

Sol-Gel is a dermatology company focused on commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

Industry

Life Sciences

Year Founded

Website

Ownership

Public

Exchange / Symbol

NASDAQ: SLGL

Public Since

Chief Executive Officer

Chairman of the Board

Chief Financial Officer

Insider Ownership

Key Investors

Employee Count

Trailing Revenues

Trailing Operating Profits

Trailing Net Income

Auditors

Investment Bankers

Law Firm

In the CEOs Own Words

Corporate Mission

Proudest Accomplishment

Next Milestone

Geographic Markets Served

Growth Drivers

Growth Headwinds

Indicia of Customer Satisfaction

Scalability

Workforce

Focus of Recruitment

Research and Development

Patent Count

Economic Sensitivity

Unique Metrics

Greatest Concern

Company Reports and Communications

Company Press Releases

SEC Filings

Reports

Podcasts

Open Questions to Management

Chatboard

Yahoo Finance

Yahoo Finance